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Abstract
Nocardiosis is a rare opportunistic disease that affects mainly
patients with deficient cell-mediated immunity, such as those
with acquired immunodeficiency syndrome (AIDS) or trans-
plant recipients. Pulmonary disease is the most common
presentation in immunosuppressed patients and approxi-
mately one-third have a disseminated disease. Primary
cutaneous nocardiosis is more frequently observed in immu-
nocompetent patients with direct inoculation of the organism
through professional exposure. The diagnosis can be chal-
lenging, as signs and symptoms are not specific and a high
index of clinical of suspicion is necessary. Although gram
stain, modified acid-fast stain, and cultures remain as the
standard diagnostic tools, novel molecular techniques have
changed the taxonomy of these organisms and, in some
instances, have facilitated their identification. The disease has
a marked tendency to recur and a high morbidity and mortality
rate in immunosuppressed patients. Treatment is usually
prolonged and an associated antibiotic treatment is preferred
for severe disease. Although sulfonamides in combination with
other antibiotics are still the treatment of choice, other
associations such as imipenem plus amikacin are preferred in
some centers. Linezolid is a useful alternative therapeutic
agent due to its oral availability and activity against most of
the isolates studied. Twenty-eight cases of nocardiosis were
diagnosed at our center between January 1989 and April 2009.
We report the epidemiologic characteristics of Nocardia spp.
observed in our institution and discuss the risk factors,
clinical features, diagnosis, and management of the disease.
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Introduction
Nocardiosis is a localized or disseminated infection caused
by the actinomycete Nocardia spp. that affects mainly
immunocompromised patients [1]. It has been reported
more frequently in patients with varying types of deficient
cell-mediated immunity, such as those with acquired
immunodeficiency syndrome (AIDS) or organ transplant
recipients, with an incidence in these groups 140–340-fold
higher than in the general population [2]. Clinical pre-
sentation can be acute, sub-acute, or, more frequently,
chronic. Nocardiosis has a high morbidity and mortality
rate, which has been reported to be between 7 and 44%
for disseminated nocardiosis. The disease also has a
marked tendency to recur. Immunocompetent patients
usually develop localized cutaneous lesions, such as cel-
lulitis, abscesses, or sporotrichoid forms [1].
Epidemiology, Pathogenesis, and Risk Factors
Nocardia spp. are ubiquitous soil organisms with more
than 50 species that have been isolated from clinical
infections [1, 3]. Nocardiosis has been reported worldwide
in all ages and ethnic groups. It is two to three times more
common in men, but there is no clear explanation for this
gender predominance [4–7]. Nocardia is not part of the
normal human flora and any isolate must be carefully
evaluated [4].
The organisms are readily aerosolized with dust,
especially in dry areas. Consequently, the respiratory tract
is the main portal of entry, with 50 to 70% of cases pre-
senting with pulmonary involvement, most commonly
with organisms representing the former N. asteroides
complex [8]. Bronchiectasis and other structural lung
abnormalities have been reported as an important risk
factor for respiratory colonization by Nocardia spp. [9].
Organisms can also be acquired by direct inoculation,
resulting in primary infections of the skin and subcuta-
neous tissues, often presenting as a localized, nodular
process. These infections can progress via lymphatic
spread to regional nodes and, occasionally, by direct
spread to contiguous joints and bones [3]. Agricultural
work represents an important risk factor, with N. brasili-
ensis being the most common infecting species. Chronic
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cutaneous infections evolving over months to years may
result in a mycetoma (actinomycetoma) [3, 10–12].
The pace and course of infection is closely related to
the immune competence of the host. Infections in immu-
nocompetent hosts are typically chronic processes, local-
ized to a single organ or region. In contrast,
hematogenous dissemination, frequently involving the
central nervous system and skin, is characteristic of
immunocompromised hosts. Nocardiosis has been ob-
served in a wide range of conditions associated with im-
paired cell-mediated immunity [13–17], including solid
organ and hematopoietic stem cell transplantation, AIDS,
hematologic and solid organ malignancies, and chronic
systemic steroid use. Patients presenting with dissemi-
nated nocardiosis should be carefully evaluated for de-
fects in host immunity.
Twenty-eight cases of nocardiosis were diagnosed at
the University Hospitals of Geneva between January 1989
and February 2009 (Table 1). These cases represent an
update of our experience since the previous report by
Matulionyte et al. [5]. Similar to other centers, we observe
nocardiosis to be an emerging disease, since four cases
were diagnosed during 2008, and three during the first
four months of 2009. This could be related to the in-
creased number of immunocompromised patients at our
center. Although earlier reports from the United States
estimated the incidence of nocardiosis at 500–1,000 cases
per year [6], it is now increasingly observed, probably due
to the rise in the number of immunosuppressed patients
over the last several decades.
At our center, 23 (82%) of 28 patients had at least one
predisposing condition associated with immunocom-
promise (Table 1). Three other patients with chronic,
structural, pulmonary disease (cystic fibrosis, chronic
obstructive pulmonary disease [COPD], and bronchiec-
tasis) were considered to be chronically colonized, but did
not develop invasive infection. In addition, three patients
had primary cutaneous nocardiosis and one developed a
septic arthritis after trauma (Table 1).
The frequency of nocardiosis in solid organ transplant
recipients varies between 0.7 and 3%, and has mostly been
reported in heart, kidney, liver, and lung transplant
recipients [18]. At our institution, 25% (7) of the patients
were solid organ transplant recipients. The incidence of
nocardiosis is approximately 340-fold higher among bone
marrow transplant recipients than in the general popula-
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Table 1
Nocardiosis characteristics of 28 patients with invasive infection at the University Hospitals of Geneva, n (%).
Characteristic Cutaneous (n = 4)a Pulmonary (n = 20)b CNS and disseminated (n = 4)c
Underlying condition
Solid organ transplantationd 6 (30) 1 (25, disseminated form)
Solid organ malignancye 1 (25) 3 (15) 1 (25)
Diabetes mellitus 3 (15) 1 (25)
HIV infection 3 (15)
Other immunodeficient conditionf 3 (15) 1 (25)
Corticosteroids 1 month previous to nocardiosis 8 (40) 2 (50)
Coinfectionsg 6 (30)
Nocardia spp.
N. asteroides 12 (60) 1 (25, disseminated form)
N. asteroides complex 2 (10) 2 (50)
N. farcinica 2 (10)
N. nova 1 (5)
N. brasiliensis 1 (25)
Not identified 3 (75) 3 (15) 1 (25)
Outcome
Cure/improvement 4 (100) 15 (75) 3 (75)
Failureh 1 (5)
Relapsei 1 (5)
Death 3 (15) 1 (25, disseminated form)
aIncluding three cases of primary cutaneous nocardiosis and one case of arthritis
bNocardia recovered only from respiratory samples (disseminated cases not included)
cIncluding three cases of isolated CNS involvement and one disseminated case (Nocardia recovered form blood, lung, and peritoneum)
dRenal in three patients, cardiac in two patients, pulmonary in one patient, and hepatic in one patient
eBreast in three patients, prostate and tongue in one patient each
fIdiopathic lymphopenia, chronic granulomatous disease, common variable immunodeficiency, multiple myeloma
gPneumocystis jirovecii pneumonia in an HIV patient, tuberculosis in a patient with cancer, CMV infection in a cardiac and in a renal transplant
recipient, Mycobacterium intracellulare, CMV, and Toxoplasma spp. infection in a cardiac transplant recipient, pulmonary aspergillosis in a liver
transplant recipient
hDefined as no initial response to treatment
iDefined as initial response followed by clinical worsening on treatment
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tion [2]. Although nocardiosis is rare within the first
month after organ transplantation, it must be considered if
aggressive immunosuppression has been used. High-dose
steroid therapy, a history of cytomegalovirus disease, and
high levels of calcineurin inhibitors have been described
as independent risk factors for Nocardia infection among
organ transplant recipients [19].
Among patients with AIDS, the incidence of
nocardiosis is approximately 140-fold higher than in the
general population [2]; patients with a low CD4 T-cell
count (less than 100 cells/mm3) are at the highest risk
[20]. In HIV-positive patients, the clinical picture of
pulmonary nocardiosis, with or without dissemination,
may be very similar to tuberculosis [21], thereby, leading
to delay in diagnosis and, subsequently, poor outcome [22].
Although the overall incidence of nocardiosis among AIDS
patients is low (between 0.1 and 0.4%), it is associated with
high morbidity and mortality rates [23, 24]. At our center,
11% (3) patients were HIV-positive (Table 1). Conventional
trimethoprim-sulfamethoxazole prophylaxis may reduce the
rate of nocardial infection in transplant recipients and AIDS
patients; however, cases have been reported in patients
receiving such treatment [25, 26].
Prolonged therapy with systemic corticosteroids cau-
ses a selective suppression of the Th1-cellular immunity
[27] and has been reported as a major predisposing factor
for pulmonary and disseminated nocardiosis. Steroids are
also frequently associated with other predisposing condi-
tions, such as chronic pulmonary disease or transplanta-
tion. At our institution, 36% (10) of the patients were on
steroid therapy at the time of nocardiosis (Table 1).
Solid organ tumors and oncohematologic malignan-
cies, with or without concurrent chemotherapy or corti-
costeroids, have been reported as important predisposing
factors for nocardiosis [5, 28–32]. At our center, 18% (5)
of the patients had solid organ malignancies and one had
an oncohematologic malignancy (Table 1).
There is no definitive evidence of person-to-person
transmission of Nocardia infection and respiratory or
contact isolation are not recommended [23].
Clinical features
No internationally accepted disease classification is
available for nocardiosis. However, commonly accepted,
standard, clinical categories are pulmonary, disseminated,
and primary cutaneous nocardiosis.
Cutaneous nocardiosis is caused mostly by N. brasil-
iensis [23, 25].
Immunocompetent patients with traumatic inocula-
tion at the infected site may develop superficial cutaneous
disease (primary cutaneous nocardiosis), lymphocutane-
ous disease (sporotrichoid nocardiosis), or actinomyceto-
mas. Lymphocutaneous disease must be differentiated
from sporotrichosis and other subcutaneous mycosis, as
the clinical presentation can be very similar, with affec-
tation of both lymphangitic vessels and lymph nodes.
Actinomycetomas caused by Nocardia spp. must be
differentiated from those produced by other actinomy-
cetes and by those produced by fungus, and although the
evolution of those caused by Nocardia is normally faster,
they cannot be differentiated clinically [33].
Pulmonary nocardiosis is caused by numerous spe-
cies and is more frequently encountered in patients with
structural pulmonary disease, as they are more suscep-
tible to colonization. The clinical presentation can be
acute, sub-acute, or chronic pneumonia, and the multi-
ple radiographic presentations include lobar infiltrates,
abscesses, cavities, pleural effusion, or pulmonary nod-
ules (Figure 1). Although there is no specific pattern,
cavities are frequently found, particularly among HIV-
infected individuals [20]. Patients chronically infected
may present weight loss and a persistent cough over
many weeks, and tuberculosis must always be excluded.
Lung abscesses produced by other bacteria and lung
cancer are other important differential diagnoses and
are very difficult to distinguish clinically. Although less
frequent, immunocompetent patients can also present
with pulmonary nocardiosis. In our case series, 71% (22)
of the patients presented with pulmonary infection, with
fever and cough (60% each) as the most frequent
symptoms.
Disseminated nocardiosis may be caused by numer-
ous species. In most cases, dissemination is from the lungs
and involves more frequently the central nervous system,
skin, and the soft tissues. This is typically observed in
severely immunocompromised patients (transplant recip-
ients, AIDS). Nocardia spp. are responsible for the initial
cutaneous or neurological clinical symptoms in some
cases, and the pulmonary affectation is evidenced only
thereafter. The involvement of the central nervous system
should always be excluded in immunosuppressed patients,
even without neurological symptoms. Cerebral abscesses
Infection 38 Æ 2010 Æ No. 2 91
Figure 1. Chest computed tomography (CT) scan. Pneumonia due to
Nocardia spp. in a renal transplant recipient.
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are frequently multiple, but there is no typical presenta-
tion (Figure 2). In our series, one patient presented with
disseminated disease, and three patients presented brain
abscesses without evidence of another infected body site,
which are unusual clinical presentations (Table 1). Clini-
cal features of the main nocardial syndromes can be seen
in Table 2.
Ocular [34–36], endovascular [37, 38], renal [39],
osteoarticular [40], and other localizations have been
described in some rare cases in different types of immu-
nosuppressed patients, and even less frequently in patients
without immunosuppression. In our series, one previously
healthy patient presented a septic arthritis after a trau-
matic inoculation. Evolution was favorable after surgical
debridement and treatment with trimethoprim-sulfa-
methoxazole. Joints and bones can be reached by direct
inoculation or by contiguous spread in immunocompetent
patients. On the other hand, they can also be reached by
hematogenous spreading from the lungs in immunocom-
promised patients with disseminated disease.
Although Nocardia infection has been reported as a
disease with a high morbidity and mortality rate, the
crude mortality rate was less elevated in our series, being
14%.
Diagnosis
The clinical and radiographic findings in pulmonary,
disseminated, and cutaneous nocardiosis are non-specific
and may be mistaken for a variety of other bacterial
infections, including actinomycosis and tuberculosis, as
well as fungal infections and malignancies affecting the
lungs, the skin, and the brain [4]. Nocardiosis must be
suspected in immunocompromised patients with acute,
sub-acute, or chronic pneumonia, or in those with central
nervous system or skin and soft tissue involvement.
Alertness to the possibility of nocardiosis can expedite
the diagnostic work-up, especially in patients with pre-
disposing factors. The diagnosis of Nocardia requires the
isolation and identification of the organisms from a
clinical specimen. Since nocardial colonies may take up
to 2 weeks to appear, it is important to notify the labo-
ratory when Nocardia infection is suspected, so that
appropriate measures can be taken to optimize the rec-
ognition and recovery of the organism. Nocardia can dis-
seminate to virtually any organ and, thus, clinical samples
can vary. As most cases are pulmonary, the most frequent
samples are sputum and bronchoalveolar lavage, or other
respiratory specimens. Other samples are skin biopsies,
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Figure 2. Brain magnetic resonance imaging (MRI) scan showing a
cerebral abscess due to Nocardia spp. in a diabetic patient. Diagnosis
was confirmed by stereotactic biopsy.
Table 2
The main clinical features of cutaneous, pulmonary, and disseminated nocardiosis.
Clinical presentation Primary cutaneous nocardiosis Pulmonary nocardiosis Disseminated nocardiosis
Susceptible patients Agricultural workers, traumatic
exposure
Chronic pulmonary disease,
deficient cell-mediated
immunity
Deficient cell-mediated immunity
Main clinical features Dermo-hypodermitis,
lymphangitis, or mycetomaa
Acute, sub-acute, or chronic
pneumonia, cavitation,
nodular infiltrates, or abscesses,
pleural effusion or empyema
Lung affectation with subcutaneous
or cerebral abscessesb; every organ
potentially affected
Main clinical differential
diagnosis
Sporotrichosis and other
subcutaneous mycoses,
fungal mycetomas
Bacterial lung abscesses,
tuberculosis, aspergillosis,
and other opportunistic fungal
infections
Bacterial brain abscesses, abscesses
in other organs, aspergillosis,
and other opportunistic fungal
infections
aBy direct inoculation or contiguous spread, the organism can reach bone and joints
bBy hematogenous dissemination from lungs. The skin and the brain are the most affected sites, but every organ can be potentially affected
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aspiration from fluid collections, cerebrospinal fluid, and
biopsy material [23].
Nocardia is rarely considered as a contaminant in the
laboratory, and each isolate must be carefully evaluated
[41]. Serology is usually not useful, as no single serological
technique can detect all of the clinically relevant species.
Moreover, antibody response is usually impaired in
immunocompromised patients [3].
Microscopic and macroscopic examination of speci-
mens submitted for culture is the first step in providing a
diagnosis [3]. Staining with modified acid-fast stain, and
especially gram stain, is particularly important to provide
a rapid presumptive diagnosis while awaiting the results of
the culture [13]. Most Nocardia are acid-fast in direct
smears if a weak acid is used for decoloration. Gram stain
and modified acid-fast stain must be considered for the
initial evaluation of a possible case of nocardiosis, and
samples may have to be repeated if the initial specimens
are negative, but there is a high clinical suspicion of
infection. Tubercle bacteria can be differentiated given
that they are microscopically different, and mycobacteria
do not stain well with gram stain and modified acid-fast
stain. Similarly, Actinomyces can be differentiated from
Nocardia, as they are not stained by modified acid-fast
stain [4]. Nocardia spp. can grow on most non-selective
media used routinely for the culture of bacteria, fungi, and
mycobacteria. In general, the colonies have a chalky white
or cotton ball appearance because of the presence of
abundant aerial filaments [23]. However, in specimens
such as sputum containing mixed flora, Nocardia colonies
can be easily covered by other bacteria with a more rapid
growing capacity. The yield can be increased by the use of
selective media such as Thayer–Martin agar with antibi-
otics, but the suspicion of Nocardia infection must be
transmitted to the laboratory. Although the growth of
Nocardia species may take from 48 h to 3 weeks, typical
colonies are usually seen after 3 to 5 days [42].
When the microorganism has been isolated, multiple
laboratory tests can be used to differentiate the species.
Initial species identification can be performed by bio-
chemical reactions. A set of nine tests allows the identi-
fication of N. asteroides sensu strictu, N. transvalensis
(N. asteroides IV), N. farcinica, N. otitidiscaviarum,
N. brasiliensis, N. pseudobrasiliensis, N. transvalensis,
N. brevicatena, and N. nova [41]. However, Nocardia
taxonomy is under continuous revision and final specia-
tion may require confirmation in some cases by molecular
techniques such as 16S rRNA sequencing, polymerase
chain reaction (PCR), and real-time PCR, which may
change the initial biochemical identification [43–45].
Agreement of molecular techniques with conventional
methods ranges between 70 and 90% [46]. However, this
technology is not available in all clinical microbiology
laboratories. Species typification is very important since
different species have different resistance profiles, and this
information is crucial in order to adjust the antibiotic
treatment [3]. The distribution of Nocardia species
according to the clinical presentation at our center is
shown in Table 1.
Although there is no specific radiologic pattern for
pulmonary or disseminated nocardiosis, some radio-
graphic findings have been reported more frequently and
can suggest the diagnosis. In pulmonary nocardiosis, nod-
ular images and cavities are frequently seen in the chest
radiograph and computed tomography (CT) scan [13, 47].
Cavities are especially common among HIV-infected
individuals [20]. Brain images frequently demonstrate
abscesses in disseminated nocardiosis [48–50], but they are
no different from those produced by other bacteria. Brain
abscesses can also mimic other conditions, particularly
malignancy and cerebral metastasis [50]. Since neurologi-
cal symptoms may be very subtle initially in patients with
disseminated nocardiosis, a brain CT scan or, preferably,
magnetic resonance imaging (MRI) should always be
performed to exclude neurological involvement [49].
Although the diagnosis can be confirmed frequently
without invasive samples, such as sputum, surgical pro-
cedures are required on some occasions to obtain speci-
mens to exclude or confirm the nocardial etiology of the
process. This may be particularly important for neuro-
logical involvement in immunocompromised patients in
whom the spectrum of microorganisms can be broader
than in immunocompetent hosts [28, 49, 50]. In this clin-
ical setting, stereotactic brain biopsy should be considered
for patients with cerebral abscesses [49, 51–53].
Treatment
As nocardiosis is a rare disease, the most appropriate
therapeutic agent, administration route, and treatment
duration have not been well established in clinical trials.
Most recommendations are based on the results of basic
research, animal models, and clinical expert opinions.
Sulfonamides have been the agents of choice for the
treatment of nocardiosis for more than 60 years. How-
ever, in patients with severe or disseminated disease, the
mortality rate remains elevated with sulfonamide mono-
therapy, and relapses are frequent. Moreover, these drugs
are associated with a high incidence of adverse events,
such as allergic reactions or severe nausea [54]. Different
species have different antimicrobial resistance profiles,
and some may be resistant to sulfonamides, as well as
particular strains [55]. For these reasons, an initial com-
bination therapy with two or more active agents is rec-
ommended for patients with disseminated or severe
nocardiosis. According to the clinical presentation, the
evolution, and the involved body site, adjuvant surgical
treatment may be necessary. Primary prophylaxis is gen-
erally not considered because of the overall low incidence
of nocardiosis [23].
Although susceptibility tests for all clinically signifi-
cant Nocardia isolates are recommended, clinicians usu-
ally start treatment empirically when these results are still
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not available. A suggested initial treatment for the main
nocardial syndromes can be seen in Table 3. For patients
with serious disease, central nervous system involvement,
and/or disseminated infection, some experts recommend a
three-drug regimen comprising trimethoprim-sulfa-
methoxazole, amikacin, and either ceftriaxone or imi-
penem, which covers all clinical isolates, as no report of
resistance to this combination has been indicated [3, 56].
Other authors consider that there is no need to include
sulfonamides in the initial regimen and that imipenem
plus amikacin is a good initial combination [5, 55]. In our
series, 92% of tested strains were sensitive to imipenem,
and all of the tested strains were sensitive to amikacin, but
other aminoglycosides were less reliable. However, the
potential problem with the imipenem/amikacin associa-
tion may be the presence of a strain resistant to the
b-lactam in a patient with central nervous system
involvement. In this clinical situation, treatment may be
insufficient due to the limited penetration of aminogly-
cosides into the central nervous system. Although er-
tapenem may be an attractive alternative to imipenem
(once-daily administration and intramuscular availability),
it was tested in our center for one strain susceptible to
imipenem, which revealed it to be ertapenem-resistant.
Thus, susceptibility within the carbapenems group can
probably not be extrapolated from imipenem. Trimetho-
prim-sulfamethoxazole was active in vitro in 84% of tes-
ted strains and intermediate in one. Although
trimethoprim-sulfamethoxazole was initially started in 15
patients, six cases had to be switched to another treatment
because of side effects or a lack of efficacy. Minocycline
was another potentially useful drug, and was tested as
susceptible in nine of ten strains tested and intermediate
in the other.
Ceftriaxone showed good activity against most of the
tested strains, except against N. farcinica isolates, which
must always be considered as resistant if sensitivity tests
are not available.
Treatment must be started and continued for several
weeks intravenously and then switched to oral therapy
after the initial clinical improvement. It is not clear if
trimethoprim-sulfamethoxazole is more active than the
sulfonamide component alone but, in some countries,
trimethoprim-sulfamethoxazole is the only intravenous
sulfonamide available.
Initially, the recommended dose is 10–20 mg of tri-
methoprim. Later, the daily dose could be decreased to
5–10 mg/kg of trimethoprim divided into 2–4 doses [54].
For immunocompetent patients with all forms of cutane-
ous nocardiosis, trimethoprim-sulfamethoxazole mono-
therapy may be adequate [11, 57] or used in combination
with moxifloxacin or ciprofloxacin, particularly for myce-
toma [58].
When the speciation and sensitivity tests are available,
treatment can be adjusted and oral agents can be consid-
ered in order to continue therapy. Other potentially useful
drugs, according to the species involved, are cephalospo-
rins (ceftriaxone, cefotaxime, and cefepime), other b-lac-
tams such as amoxicillin–clavulanic acid, minocycline,
fluoroquinolones (especially moxifloxacin, which is more
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Table 3
Initial antimicrobial treatment for main nocardial syndromes while awaiting species identification and susceptibility tests.
Primary cutaneous nocardiosis Pulmonary nocardiosis Disseminated nocardiosis
Suggested initial treatment TMP/SMX TMP/SMX Imipenem + amikacin
TMP/SMX + fluoroquinolone TMP/SMX + ceftriaxone TMP/SMX + imipenem + amikacin
TMP/SMX + moxifloxacine TMP/SMX + ceftriaxone + amikacin
Imipenem + amikacin
Doses 10 mg/kg/d of TMPa 10–20 mg/kg/d of TMPa 500 mg qid + 15 mg/kg/d qd
Ciprofloxacin 500–750 mg bid 10–20 mg/kg/d of TMPa
+ 2,000 mg qd
10–20 mg/kg/d of TMPa + 500 mg
qid + 15 mg/kg/d qd
Moxifloxacine 400 mg qd 10–20 mg/kg/d of TMPa
+ 400 mg qd
10–20 mg/kg/d of TMPa + 2,000 mg
qd + 15 mg/kg/d qd
500 mg qid + 15 mg/kg/d qd
Main side effects Rash, bone marrow suppression,
urinary lithiasis
Rash, bone marrow suppression,
urinary lithiasis renal toxicity,
hypersensitivity
Rash, bone marrow suppression,
urinary lithiasis renal toxicity,
hypersensitivity
Comments A fluoroquinolone must be
considered for deep
infections, especially
mycetoma
TMP/SMX monotherapy only in
immunocompetent patients
with mild disease. Combination
therapy is preferred in the
immunocompromised
Linezolid could replace any of the
proposed drugs. At least 2 week
of initial IV treatment is
recommended. Surgical treatment
must be considered for deep
abscesses
References [3, 9, 22, 56–58] [3–5, 55, 56] [3, 5, 55, 56, 60–62]
TMP/SMX trimethoprim-sulfamethoxazole; qd once a day; bid twice a day; qid four times a day
aDivided into three doses
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active than ciprofloxacin), and linezolid. Most of the iso-
lates of N. farcinica are resistant to the cephalosporins, but
cephalosporins are very active against N. asteroides type
VI, N. nova, and N. abscessus. The latter is the species that
is more frequently resistant to imipenem. The fluoro-
quinolones are active to most of the N. farcinica and N.
brasiliensis strains. N. brasiliensis is also frequently sus-
ceptible to amoxicillin–clavulanic acid [3].
Linezolid has shown very significant in vitro activity
against most of the species and strains tested [59]. Al-
though clinical experience is still limited, there are some
reports of good clinical response even with central ner-
vous system involvement [60–62]. Thus, linezolid has be-
come an attractive alternative to trimethoprim-
sulfamethoxazole, imipenem, or amikacin for the empiri-
cal initial treatment and can be administered orally for the
follow-up treatment.
However, in a recent report, although the number of
patients was small (n = 11), 45% developed myelosup-
pression and 18% neuropathy as a side effect of linezolid
treatment for nocardiosis [61]. In our institution, linezolid
was used for one immunosuppressed patient after tri-
methoprim-sulfamethoxazole intolerance, but it was
stopped for thrombocytopenia. Moreover, the cost of this
agent still remains very high.
The duration of therapy is variable and depends on
the site of the lesions and the patient immune status.
Primary cutaneous nocardiosis can be treated for 1–
3 months. However, mycetoma requires more prolonged
therapy. Pulmonary and disseminated nocardiosis without
central nervous system involvement should be treated for
6 months at least [23]. For patients with central nervous
system involvement, the duration must be established
according to clinical and imaging responses, but it usually
needs to be continued for a year or longer. In HIV-in-
fected patients with a low CD4 T-cell count and trans-
planted patients, a secondary prophylaxis with an active
oral agent needs to be maintained until the immune status
improves [20].
Some nocardiosis sites may require adjunctive surgi-
cal treatment, particularly for patients with brain ab-
scesses. However, the optimal treatment approach has not
been established and nocardial brain abscesses have been
managed either conservatively with stereotactic aspira-
tions or with open craniotomy and enucleation [49, 63,
64]. Thus, each case needs a careful multidisciplinary
evaluation by the primary physician, the infectious dis-
eases specialist, and the surgeon. Mycetoma, some ocular
infections, and rare cases with other body sites involve-
ment may require surgical treatment [37, 65–69].
The disease has a tendency to recur and exacerbations
can occur even during maintenance therapy if antibiotic
concentrations are not optimal. Thus, doses and antibiotic
levels must be carefully monitored in immunosuppressed
patients, particularly if the clinical evolution is not
favorable [16].
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